Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LCB84
- Development stage
- Phase 2
- Lead developer
- LigaChem Biosciences, Inc.
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
LCB84 is a next-generation antibody-drug conjugate (ADC) that targets the trophoblast cell surface antigen 2 (TROP2), which is highly expressed in various cancer cells. The drug consists of an anti-TROP-2 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent tubulin inhibitor. Upon binding to TROP-2 on tumor cells and internalization, MMAE is released inside the cell via cleavage by lysosomal enzymes such as beta-glucuronidase. This release disrupts microtubule polymerization, leading to cell cycle arrest and apoptosis of the cancer cell[1][6][7]. Developed using LegoChem Biosciences' proprietary ADC platform technology with a licensed Trop2 antibody from Mediterranea Theranostic Srl, LCB84 has demonstrated differentiated safety and efficacy profiles in preclinical studies across multiple cancers[6]. It is currently being evaluated in Phase 1/2 clinical trials for advanced solid tumors both as a single agent and in combination with an anti-PD-1 antibody[4][5].
- Other names
- anti-TROP-2/MMAE antibody-drug conjugate LCB84
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on LCB84.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LCB84.